Kura Oncology, Inc.
Financials
Valuation Metrics
Kura Oncology, Inc.'s Market Cap is $869M. At end of 2025 it was $915M. Ranked #2458 of 3,116 in US market (top 79%), #1009 of 1,472 on NASDAQ (top 69%), #182 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 69%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $869M | US#2,458/3,116 Sec#182/265 |
| Revenue | $76M | US#2,710/3,116 Sec#134/265 |
| Net Income | $-297M | US—/3,116 Sec—/265 |
| Total Assets | $588M | US#2,696/3,116 Sec#142/265 |
| Net Assets | $48M | US#2,853/3,116 Sec#222/265 |
| Employees | 260 | US#2,435/3,116 Sec#117/265 |
| Value | ||
| P/B | 17.95x | US#2,773/3,116 Sec#215/265 |
| P/S | 11.41x | US#2,747/3,116 Sec#124/265 |
| FCF Yield | -13.51% | US—/3,116 Sec—/265 |
| Profitability | ||
| ROA | -50.49% | US#2,986/3,116 Sec#215/265 |
| Op. Margin | -417.71% | US#2,774/3,116 Sec#149/265 |
| Revenue Growth | -7.70% | US#2,509/3,116 Sec#142/265 |
| Financial Health | ||
| Debt Ratio | 1113.67% | US#2,748/3,116 Sec#228/265 |
| Total Debt | $24M | US#2,715/3,116 Sec#181/265 |
| FCF | $-117M | US#2,664/3,116 Sec#159/265 |
| Cash | $70M | US#2,422/3,116 Sec#203/265 |
| Current Ratio | 4.73x | US#498/3,116 Sec#149/265 |
| Performance | ||
| 1Y Return | -4.67% | US#1,729/3,116 Sec#144/265 |
| 1M Return | -8.08% | US#2,102/3,116 Sec#143/265 |
| From 52W High | -29.57% | US#1,737/3,116 Sec#104/265 |
| 1Y MDD | -39.04% | US#1,889/3,116 Sec#113/265 |
| Trading | ||
| Volume | 1,360,239 shares | US#1,101/3,116 Sec#107/265 |
| Trading Value | $14M | US#2,005/3,116 Sec#153/265 |
| Per Share | ||
| EPS | $-3.34 | US—/3,116 Sec—/265 |
| BPS | $0.55 | US#2,742/3,116 Sec#216/265 |
Company Info
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.